key: cord-0716792-e2za8pui
authors: Jaiswal, N; Bhatnagar, M; Shah, H
title: N-acetycysteine: a potential therapeutic agent in COVID-19 infection
date: 2020-07-24
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.110133
sha: adfe2490435e15f5420c3f0cd64d5c4c02ef1173
doc_id: 716792
cord_uid: e2za8pui

COVID-19 is an overwhelming pandemic which has shattered the whole world. Lung injury being the main clinical manifestation, it is likely to cause COPD (chronic obstructive pulmonary disease) and ARDS (acute respiratory distress syndrome). The possible cause behind this might be redox imbalance due to viral infection. Elevation in Glutathione (GSH) levels by administration of its promolecule might be effective. N-acetylcysteine is one such drug with potency to scavenge Reactive Oxygen Species, least side effects, and an effective precursor of glutathione. Consequently we hypothesize that N-acetylcysteine along with the conventional treatment may be treated as a potential therapeutic solution in cases of COVID- 19 patients.

. The toxicity of severe lungs injury is supposed to be due to free radicals generation together with deteriorating innate immunity and activation of transcription factors [5] . Experimental and clinical studies confirmed the role of GSH against inflammatory pathologies of the lungs by attenuating Oxidative Stress [6]. This suggests that endogenous glutathione depletion may be a possible consequence of progression of COVID-19 patients from mild to severe illness. Supplementation of glutathione directly is difficult due to its short half life and impermeability to many biological membranes, thus its precursor N--acetyl-cysteine could be used to elevate its intracellular levels.

N-acetylcysteine is the promolecule to cysteine, a potent precursor of glutathione, enhancing the intracellular sulphydryl pool as a powerful antioxidant. NAC liquefies mucus by opening disulfide bonds in mucoprotein, reduces viscosity of bronchial and lung secretions and recovers oxygen saturation in the blood. NAC directly inactivates reactive electrolytes and free radicals non-enzymatically and maintains oxidant/ antioxidant balance in cells. At doses more than 1200mg, it acts as an antioxidant by reducing the formation of pro-inflammatory cytokines, 4 such as IL-9 and TNF-α and also shows vasodilator property by increasing cyclic GMP levels and contributing to the regeneration of endothelial-derived relaxing factor. A placebo controlled study by Zhang et. al., [7] has investigated the antioxidant properties of NAC in exacerbations of chronic obstructive pulmonary disease. NAC also protects against H9N2 swine influenza virusinduced acute lung injury (ALI) thus dictating its therapeutic importance in ALI caused due to influenza virus [8] . Studies also revealed that NAC treatment in ARDS patients can improve the outcome of the patients by rising total thiol molecule and anti-oxidant molecules [9] . This shows the potential benefits of using NAC as therapeutic agent in these patients.

There is substantial evidence to support our hypothesis that N-acetyl-cysteine has a potential to be used as a therapeutic agent in the treatment of COVID-19 patients. It is a drug with potency to scavenge Reactive Oxygen Species (ROS), least side effects, and an effective precursor of glutathione. Our hypothesis is worth proving in well designed clinical studies that may benefit in the treatment of COVID-19 patients.

Prior presentation: No data from this manuscript were presented in a scientific forum before. 

Influenza virus replication in lung epithelial cells depends on redox-sensitive pathways activated by NOX4-derived ROS. Cellular microbiology

GSH and analogs in antiviral therapy. Molecular aspects of medicine

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine

Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury

Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen

N-acetyl-lcystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury

N-acetyl-lcystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury

Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Human & experimental toxicology

There is no conflict of interest with the suggested hypothesis